SCHEMBL7912480

SCHEMBL7912480

CN(Cc1ccc(F)cc1)C(=O)C1(c2ccccc2)CCN(C(=O)c2ccc(N3CCS(=O)(=O)CC3)cc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
SLC6A7 Q99884 1/20 0.45
NPSR1 Q6W5P4 2/20 0.42
TACR3 P29371 5/20 0.42
LMNA P02545 4/20 0.41
USP2 O75604 4/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 2/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
MAPK10 P53779 1/20 0.41
CYP3A4 P08684 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
TSHR P16473 2/20 0.40
CYP2D6 P10635 1/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3095655 0.80 MEN1 (0.51) MEN1KMT2ASLC6A7NPSR1LMNA
SCHEMBL13092248 0.79 MEN1 (0.45) MEN1KMT2ASLC6A7NPSR1USP2
SCHEMBL3099738 0.79 KDM4E (0.53) MEN1KMT2ASLC6A7LMNAUSP2
SCHEMBL13092273 0.77 TACR3 (0.40) MEN1KMT2ATACR3LMNAALDH1A1
SCHEMBL13182985 0.75 GFER (0.52) KMT2ATACR3LMNASMN1; SMN2
SCHEMBL7914218 0.74 HSP90AA1 (0.42) MEN1KMT2ASLC6A7LMNAMAPT
SCHEMBL7907440 0.74 TSHR (0.44) USP2KDM4EHTTCYP3A4SMN1; SMN2
SCHEMBL13092252 0.74 TSHR (0.42) USP2KDM4ECYP3A4SMN1; SMN2ALDH1A1
SCHEMBL13689841 0.72 MEN1 (0.62) MEN1KMT2ASLC6A7NPSR1LMNA
SCHEMBL7899556 0.72 OPRM1 (0.51) TACR3LMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 MEN1 4869/4885KMT2A 1488/4885SLC6A7 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.